Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific; E-box binding activity; and bHLH transcription factor binding activity. Predicted to contribute to DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in positive regulation of transcription by RNA polymerase II; regulation of stem cell differentiation; and stem cell population maintenance. Predicted to act upstream of or within several processes, including epithelial cell differentiation; paraxial mesoderm development; and post-anal tail morphogenesis. Predicted to be located in nucleus. Predicted to be part of RNA polymerase II transcription regulator complex. Orthologous to human TCF15 (transcription factor 15); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; alpha-Zearalanol.
[Chir 99021 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with Tretinoin] results in increased expression of TCF15 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCF15 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCF15 mRNA